1stOncology™: Cancer Intelligence Service – Page 474 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Flare Therapeutics Announces Three Upcoming Poster Presentations at AACR Annual Meeting 2026

On April 6, 2026 Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, reported that it will present three posters at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, which is being held from April 17-22, 2026, in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The poster presentations will include preclinical data for the company’s two lead programs, FX-909, a first-in-class, orally available PPARG inhibitor designed to target the underlying luminal lineage biology of urothelial cancer and FX-111, a novel and highly differentiated potent and selective degrader for ARON, the transcriptionally active, hormone-bound androgen receptor for prostate cancer.

FX-909 Presentation Details:

Luminal urothelial carcinoma (UC), characterized by high PPARG expression, represents the majority of UC cases and is associated with poor clinical outcomes. In a Phase 0 study, FX-909, a first-in-class oral PPARG inhibitor, demonstrated intratumoral penetration and on-target activity, including dose-dependent PPARG modulation, increased tumor apoptosis, and enhanced CD8⁺ T-cell infiltration. Notably, combination with anti-PD-1 further amplified immune activation and suppression of tumor proliferation pathways. These findings support the potential of FX-909 to modulate the tumor microenvironment and warrant further clinical evaluation in UC.

Title: Phase 0 Intratumoral Microdevice Study of FX-909 in Bladder Cancer Demonstrates On-Target Anti-Tumor Activity and Immune Modulation, Enhanced in Combination with Anti-PD-1

Abstract ID: CT111 / 3
Session: Phase 0 and First-in-Human Phase I Clinical Trials
Date, Time: April 20, 2026, 2:00 p.m. – 5:00 p.m. PT
Location: Section 51
FX-111 Presentation Details:

Metastatic castration-resistant prostate cancer (mCRPC) remains largely driven by androgen receptor (AR) signaling, with resistance to current AR inhibitors posing a major clinical challenge. Real-world data identified distinct AR/KLK3-defined subgroups, with AR copy number amplification linked to increased AR signaling and poorer outcomes, reinforcing the central role of AR-driven biology in disease progression and identifying a high-risk, AR-driven population.

Title: AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor (ARSI) resistance and highlight the need for AR-directed therapeutic innovation in metastatic castration resistance prostate cancer (mCRPC)

Abstract ID: 3910 / 16
Session: Molecular Targeted Therapy
Date, Time: April 20, 2026, 2:00 p.m. – 5:00 p.m. PT
Location: Section 47
FX-111 is a novel and highly differentiated, potent and selective degrader for ARON, the transcriptionally active, hormone-bound androgen receptor. This approach offers the potential to overcome key vulnerabilities of conventional therapies that target AROFF, particularly in high-risk AR-driven disease, and has broad potential across prostate cancer at all stages.

Title: Discovery of FX-111, a first-in-class heterobifunctional degrader of transcriptionally active androgen receptor (ARON), to treat patients with AR-driven prostate cancer

Abstract ID: 5784 / 11
Session: Proximity-Induced Drug Discovery 2
Date, Time: April 21, 2026, 2:00 p.m. – 5:00 p.m. PT
Location: Section 15

(Press release, Flare Therapeutics, APR 6, 2026, View Source [SID1234664193])

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

On April 6, 2026 Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, reported that the company will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, CA, from April 17 – 22, 2026. The presentations demonstrate Biodesix capabilities in blood- and tissue-based testing and monitoring across a range of applications.

"Biodesix expertise in test discovery and development, regulatory, reimbursement, and commercialization provides an exceptional level of service for our partners across a range of applications. The AACR (Free AACR Whitepaper) presentations showcase basic research through clinical applications and pre-validated assays available for biopharma and life science partners, as well as advancements in our pipeline efforts. The data are reinforced by more than a decade of experience supporting the clinical development and commercialization of new diagnostics and therapeutics," said Gary Pestano, PhD, Chief Scientific Officer, Biodesix.

"The depth of experience and success across the Biodesix team, spanning real-world clinical care and cutting-edge research, will be on full display at this year’s AACR (Free AACR Whitepaper). It is especially exciting to see our genomic and proteomic technologies, combined with advanced data informatics, translating into meaningful clinical impact in our pipeline product concepts while also fueling strong momentum in our Development Services business as we move into 2026," said Scott Hutton, CEO, Biodesix.

Tumor & Immune Profiling Expertise

Biodesix oral and poster presentations highlight diverse technology platforms, rapid turn-around times for our clinical tests, and extensive capabilities in immune and tumor profiling using mass spectrometry, Bio-Rad Droplet Digital PCR, and Thermo Fisher Ion AmpliSeq platforms. In addition, Biodesix has validated a new clinical myeloid panel on the Thermo Fisher Ion Torrent Genexus System. The platform supports an automated clinical next-generation sequencing (NGS) workflow and can deliver sequencing results in as little as 24 hours.

Sunday, April 19 | 3PM–5PM PST | Oral Presentation | Room 17, Mezzanine Level, Convention Center
Title: Real-world analysis of NSCLC* variant-level frequencies from liquid biopsy testing in diverse U.S. populations

Monday, April 20 | 2PM–5PM PST | Poster Section 41
Poster: 3743. ddPLEX EGFR/KRAS/BRAF: A highly multiplexed droplet digital PCR (ddPCR) panel for ultra-sensitive NSCLC biomarker detection

Wednesday, April 22 | 9AM–12PM PST | Poster Section 39
Poster: Blood-based proteomic profiling reveals novel biomarkers of Neuroendocrine Prostate Cancer

Monday, April 20 | 2PM–5PM PST | Poster Section 44
Title: Performance validation of a next generation sequencing myeloid assay on an integrated nucleic acid purification and sequencing system

Molecular Residual Disease (MRD) Product Pipeline

Another set of presentations highlights a novel, multi-omic approach to MRD monitoring. Thermo Fisher Scientific, Bio-Rad Laboratories, and Memorial Sloan Kettering Cancer Center will co-present new data on proteomic and genomic biomarkers as well as bioinformatics workflows central to the Biodesix MRD pipeline tests.

Monday, April 20 | 12:30PM | Spotlight Theater B – Sails Pavilion – Conv Ctr
Title: Leveraging Droplet Digital PCR* (ddPCR) for MRD Detection and Monitoring in Solid Tumors and Heme Malignancies

Tuesday, April 21 | 2PM–5PM PST | Poster Section 1
Poster: 5437. Sensitive detection of rare cfDNA variants utilizing molecular technologies and a novel informatics platform: A combined genomic and proteomic MRD application.

Wednesday, April 22 | 9AM–12PM PST | Poster Section 45
Poster: 7828. Development of a comprehensive tumor-informed ctDNA workflow for ultrasensitive molecular residual disease (MRD) detection using diverse tumor profiling inputs

The full abstracts for Biodesix and a list of all abstracts being presented at the AACR (Free AACR Whitepaper) Annual Meeting can be found here.

ddPCR technology is a trademark of Bio-Rad Laboratories, Inc.
Ion Torrent Genexus System and Ion AmpliSeq Platform are trademarks of Thermo Fisher Scientific.
NSCLC is the acronym for Non-Small Cell Lung Cancer.

(Press release, Biodesix, APR 6, 2026, View Source [SID1234664192])

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

On April 6, 2026 Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) reported that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds ("MFW") at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place on April 17-22, 2026, in San Diego.

Venkat Nelabhotla, CEO of Vyome, stated that, "There are currently no FDA approved drugs to treat malodor and other symptoms of MFW. We plan to have FDA interactions in Q2 2026 on the pivotal study design. Recent third-party analysts estimated the total addressable U.S. market to be approximately USD 2.2 billion. Inflammation is one of the biggest healthcare problems facing the world today."

The research will be presented at the session "Phase II and Phase III Clinical Trials in Progress." Vyome will highlight mechanistic insights together with detailed clinical data comparing the VT-1953 active treatment with vehicle treatment in a Phase 2 study. VT-1953 is a first-in-class treatment for malodor and other symptoms of MFW in advanced cancer patients, which acts by a dual mechanism of action, inhibiting DNA Gyr and modulating MD2/TLR interactions, an inflammatory signal. MFW is a rare, debilitating condition that occurs in ~10% of advanced cancer patients, severely impacting the quality of life.

"We are delighted that AACR (Free AACR Whitepaper) found our data compelling for presentation at the annual meeting. Based on our promising clinical data underpinned by strong mechanistic alignment, we are advancing VT-1953 into pivotal studies," said Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School, Co-founder and Board member of Vyome.

The details of the presentation at the 2026 AACR (Free AACR Whitepaper) Annual Meeting are:

American Association for Cancer Research Annual Meeting 2026, San Diego

Date: April 21, 2026, 9:00 AM – 12:00 PM

Session title: (PO.CTP01.03) Phase II and Phase III Clinical Trials in Progress

Presentation number and title: CT208 / 3 – Final results from a phase 2 trial testing safety and efficacy of VT-1953 topical gel in patients with malodorous malignant fungating wound

Authors: Arshit Narang, MBBS, Prashant Prakash Lad, MD, Shiladitya Sengupta PhD

(Press release, Vyome Therapeutics, APR 6, 2026, View Source [SID1234664191])

ABION Presents Preclinical Data at AACR Showing IFN-β Antibody Fusion ABN202 Outperforms TROP2-Targeting ADCs

On April 6, 2026 ABION (KOSDAQ, 203400), a precision oncology therapeutics developer, reported that its next-generation immuno-oncology candidate, ABN202, demonstrated a superior anti-cancer mechanism compared with TROP2-targeting antibody-drug conjugates (ADCs) in preclinical studies.

The findings will be presented as a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (AACR 2026), to be held April 17–22 in San Diego, USA.

ABN202 is a next-generation immuno-oncology drug candidate based on the company’s proprietary iRAC (Interferon-β Antibody Conjugate) platform, designed to enable both direct tumor cell killing and robust immune activation. In the study, ABN202 demonstrated a superior anti-cancer mechanism compared with currently approved TROP2-targeting ADCs.

Notably, ABN202 overcame resistance to TROP2-targeting ADCs and showed superior anti-tumor efficacy compared with ADCs combined with anti-PD-1 immune checkpoint inhibitors in preclinical models. In addition, ABN202 induced sustained and systemic CD8-positive T cell-mediated immune responses, suggesting the potential for durable anti-tumor immunity.

These findings suggest that ABN202 represents a novel immuno-oncology strategy capable of overcoming resistance associated with existing ADC therapies, highlighting its strong potential as a new treatment option for patients with solid tumors who have failed prior ADC-based therapies.

ABION’s first-in-class iRAC platform can be applied not only to TROP2-targeting antibodies but also to a broad range of solid tumor targets. This platform’s versatility positions iRAC as a promising next-generation immuno-oncology approach with potential pipeline expansion opportunities.

Dr. Young Kee Shin, CEO/CTO of ABION, said, "These results highlight the potential of a differentiated IFN-β-based immuno-oncology strategy to overcome resistance to current ADC therapies. Based on these encouraging preclinical findings, we are also actively exploring strategic partnership opportunities for ABN202, including collaborations at the preclinical stage."

(Press release, ABION, APR 6, 2026, View Source;Antibody-Fusion-ABN202-Outperforms-TROP2-Targeting-ADCs [SID1234664190])

K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models

On April 6, 2026 Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan), reported an upcoming presentation of non-clinical data for K‑679, its novel antibody drug-loaded unimicelle conjugate (ADUC) with unprecedented drug loading capacity. The compound, developed using Kowa’s proprietary micelle technology, has demonstrated tumor-selective pharmacokinetics, extensive intratumoral distribution, and superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugates (ADCs). The data will be presented at The American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 to be held in San Diego, California, from April 17 to 22, 2026.

Presentation Details
Presentation Title: Selective intratumoral distribution and post-T-DXd activity of K-679, an ultra-high-DAR EGFR-targeted antibody drug-loaded unimicelle conjugate (ADUC)
Session Title: Antibody Technologies and Platforms 2
Presentation Date and Time: April 21, 2026, 9:00 a.m. – 12:00 p.m. CST (10:00 a.m. – 1:00 p.m. ET)
Poster Number: 4396
Presenter: Hideo Yoshida

The abstract of the presentation is available at
AACR Annual Meeting 2026 Itinerary Planner | Presentation

More information about the AACR (Free AACR Whitepaper) Annual Meeting 2026 can be found on the event website at the following link: AACR (Free AACR Whitepaper) Annual Meeting 2026 | Meetings | AACR (Free AACR Whitepaper)

About K-679
K-679 is an Antibody Drug-loaded Unimicelle Conjugate (ADUC), a novel type of ADC using Kowa’s proprietary micelle technology, currently in nonclinical development. The conjugate combines an anti-EGFR antibody with drug (DM1)-loaded unimicelles, which incorporate substantial quantities of payloads into a single-chain polymer. This innovative approach achieves an ultra-high DAR (Drug-to-Antibody Ratio) of approximately 45 DM1 molecules per antibody, significantly higher than conventional ADCs.

In non-clinical studies, K-679 has demonstrated tumor-selective pharmacokinetics, extensive intratumoral distribution, and concordant spatial pharmacodynamic effects in xenograft models, compared with a benchmark antibody-drug conjugate (ADC). K-679 also showed anti-tumor activity in colorectal patient-derived xenograft (PDX) models with low and heterogeneous epidermal growth factor receptor (EGFR) expression.

(Press release, Kowa, APR 6, 2026, View Source [SID1234664189])